News Poxel taking two shots at NASH as pharma waits on FDA's OCA ... Intercept’s obeticholic acid (OCA) is under review in the potentially lucrative fatty liver disease non-alcoholic steatohepatitis (NA
News Trial sets up 2020 filing for Poxel's novel diabetes drug French biotech Poxel has positive phase 3 data for a new type of oral therapy for type 2 diabetes, setting up a first filing in Japan next year.
News Ramaswamy's Roivant signs diabetes drug deal with Poxel Biotech entrepreneur hopes to bounce back from Alzheimer's disappointment
News The NHS 10-year plan arrives – what are the highlights? After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new 10-year plan for the NHS.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face